Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”) reported three board-level changes that will take effect or be confirmed on 27 March 2026.
Resignation of Non-Executive Director • Dr. Ni Jia will step down as Non-Executive Director on 27 March 2026 to focus on future business commitments. • Dr. Ni confirmed no disagreement with the board and no matters requiring shareholder attention. The board expressed appreciation for his service.
Proposed Appointment of Non-Executive Director • The board has nominated Dr. Wu Fenglan, aged 42, as a Non-Executive Director; the appointment is subject to shareholder approval at the forthcoming annual general meeting (AGM). • Dr. Wu brings over 15 years of biopharma and healthcare experience, including senior roles at GlaxoSmithKline, Zai Lab, China Renaissance, Gritgen Therapeutics (co-founder & CEO) and, most recently, Shanghai Zhengxingu Investment Management as Managing Director. • Upon approval, Dr. Wu will serve until the end of the current board’s first term (not exceeding three years) and will not receive director’s emolument. She holds no shares in Leads Biolabs and has no relationships with substantial or controlling shareholders. • A circular detailing her election will be dispatched ahead of the AGM.
Nomination Committee Adjustment • Effective 27 March 2026, Independent Non-Executive Director Dr. Zhang Hongbing becomes Chairperson of the Nomination Committee. • Dr. Kang Xiaoqiang ceases to be chairperson but remains a committee member; the committee’s overall composition is otherwise unchanged.
Board Composition at Announcement Date (27 March 2026) Executive Directors: Dr. Kang Xiaoqiang (Chairman & CEO), Dr. Lai Shoupeng, Mr. Zuo Honggang Non-Executive Directors: Mr. Zhang Yincheng, Dr. Chen Renhai (Dr. Ni Jia until 27 March 2026; Dr. Wu Fenglan pending AGM approval) Independent Non-Executive Directors: Dr. Zhang Hongbing, Mr. Du Yilong, Ms. Du Jiliu
The company will publish the AGM notice and related documents on the websites of the Hong Kong Stock Exchange and Leads Biolabs in due course.